Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies

Table 1

Demographic and clinical characteristics of nine children with transfusion dependent hemoglobinopathies that received oral solution of deferiprone (Ferriprox 100 mg/mL).

Characteristics	𝑁
Age (years)	2–10, mean 6.5
Male : Female	5 : 4
𝛽-Thalassemia major	6
Thalassemia intermedia	2
Sickle/β thalassemia	1
Red blood cell transfusions during the last year	Range 8–15, mean 10.6
Chelation therapy with deferoxamine before the initiation of the study	𝑁=2; mean dose = 35 mg/kg/d; mean duration of use = 1.5 years
Splenectomy	1
Oral liquid deferiprone dosage	50–100 mg/Kg/d, mean 75.2
Duration of oral liquid deferiprone (months)	Range 15–31, mean 21.5